Liège, Belgium, 30 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces an update on the clinical study progress for its two lead Estetrol (E4) based product candidates, Estelle® (E4 Freedom) and Donesta® (E4 Relief).
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024